Skip to main content
Clinical Trials/NCT02569905
NCT02569905CompletedPhase 4

Tumor Hospital of Guangxi Medical University, China

Guangxi Medical University1 site in 1 country166 target enrollmentStarted: April 2014Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
166
Locations
1
Primary Endpoint
shivering

Study Overview

Brief Summary

Shivering is an early postoperative complication during the postoperative recovery period, and there is no clear consensus about the best way for its prevention. The aim of the study was to compare the efficacy and accompanying side effects of prophylactic flurbiprofen with that of parecoxib or placebo for reducing postoperative shivering.

Detailed Description

154 patients with American Society of Anesthesiologists physical status I-II, who were scheduled for colorectal operation under general anesthesia, were randomly assigned to receive flurbiprofen (Group F), parecoxib sodium (Group P ) or normal saline(Group S)40min before the end of surgery. Hemodynamic parameters were monitored. The occurrence of shivering postoperative nausea and vomiting were recorded during the recovery period. And visual analogue score (VAS) and ramsy sedation scale (RSS) were also recorded.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
21 Years to 62 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • One hundred and sixty-six, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the prospective, randomized, double-blind clinical study.
  • All patients who were from 21 to 62 years old and body mass index 19-35 in tumor hospital of Guangxi medical university (State of China) from April 2014 to April 2015 were included.

Exclusion Criteria

  • Patients with cardiac, pulmonary, hepatic, renal, thyroid, or neuromuscular disease, and those who took chronic drug or abused alcohol were excluded.
  • Another patients with hypertension, gastrointestinal bleeding, an initial core temperature >37.5℃ or <36.5℃, a history of allergy to non- steroidal anti-inflammatory drugs (NSAIDs) or other agents to be used, and inability to cooperate were also excluded in this study.
  • Another patients with blood loss during operation>400ml, a need for blood transfusion during surgery, duration of operation>4h and surgical procedures changed were excluded.

Arms & Interventions

Groups Flurbiprofen

Active Comparator

Fifty-two, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.

Intervention: flurbiprofen (Drug)

Groups Parecoxib sodium

Active Comparator

Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.

Intervention: parecoxib sodium (Drug)

Group Saline

Placebo Comparator

Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.

Intervention: saline (Drug)

Outcomes

Primary Outcomes

shivering

Time Frame: in one hour after extubation.

Secondary Outcomes

  • visual analogue score(at the time of extubation, 30min and 60min after extubation.)
  • sedation scores(at the time of extubation, 30min and 60min after extubation.)
  • incidence of postoperative nausea and vomiting(in one hour after extubation.)

Investigators

Sponsor
Guangxi Medical University
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

xueke du

anesthesiologists

Guangxi Medical University

Study Sites (1)

Loading locations...

Similar Trials